Medical Technology

APEX Ventures

Check: €500K-€2.5M, as published by APEX Ventures.

Golnaz Borghei invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.

APEX Ventures

Check: €500K-€2.5M, as published by APEX Ventures.

Olivia Doppler supports APEX Ventures, whose published strategy is: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.

APEX Ventures

Check: €500K-€2.5M, as published by APEX Ventures.

Anne Glover invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.

APEX Ventures

Check: €500K-€2.5M, as published by APEX Ventures.

Hermann Hauser invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.

APEX Ventures

Check: €500K-€2.5M, as published by APEX Ventures.

Tim Hos invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.

APEX Ventures

Check: €500K-€2.5M, as published by APEX Ventures.

Ion Hauer invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.

Ohio Innovation Fund

Check: $500K-$4M, as published by Ohio Innovation Fund.

Bill Baumel invests or supports investments through Ohio Innovation Fund's published strategy: Back transformative, disruptive and breakthrough founders in AI, medtech, AR/VR, cybersecurity, SaaS and biotech, while providing hands-on support through key value inflection points.

Ohio Innovation Fund

Check: $500K-$4M, as published by Ohio Innovation Fund.

Michael Hughes invests or supports investments through Ohio Innovation Fund's published strategy: Back transformative, disruptive and breakthrough founders in AI, medtech, AR/VR, cybersecurity, SaaS and biotech, while providing hands-on support through key value inflection points.

Ohio Innovation Fund

Check: $500K-$4M, as published by Ohio Innovation Fund.

Mike Triplett invests or supports investments through Ohio Innovation Fund's published strategy: Back transformative, disruptive and breakthrough founders in AI, medtech, AR/VR, cybersecurity, SaaS and biotech, while providing hands-on support through key value inflection points.

Ohio Innovation Fund

Check: $500K-$4M, as published by Ohio Innovation Fund.

Jeff Schumann is listed in a Venture Advisor capacity at Ohio Innovation Fund. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

Ohio Innovation Fund

Check: $500K-$4M, as published by Ohio Innovation Fund.

Faith Voinovich invests or supports investments through Ohio Innovation Fund's published strategy: Back transformative, disruptive and breakthrough founders in AI, medtech, AR/VR, cybersecurity, SaaS and biotech, while providing hands-on support through key value inflection points.

Cottonwood Technology Fund

Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.

Dave Blivin contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.

Cottonwood Technology Fund

Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.

Alain le Loux contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.

Cottonwood Technology Fund

Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.

Lee Rand contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.

Cottonwood Technology Fund

Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.

Ytsen van der Meer contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.

Cottonwood Technology Fund

Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.

Sabine Jansen contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.

Cottonwood Technology Fund

Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.

Shinjan Dasgupta contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.

Cottonwood Technology Fund

Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.

Daan Boekhoudt contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.

Cottonwood Technology Fund

Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.

Charles Call contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.

Cottonwood Technology Fund

Check: Cottonwood publishes a $1M-$3M first-investment range for seed-stage companies.

Alan Abbott contributes to Cottonwood Technology Fund's published strategy: Lead early rounds in patent-based hard-science and deep-technology companies in the U.S. Southwest and Northern Europe.

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Marc Subirats invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Marta G. Zanchi invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Jordi Pedrol is listed in a Head of Finance capacity at Nina Capital. No person-specific investment authority is inferred; the firm's mandate is retained only as shared context.

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Sebastian Anastassiou invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Yahel Halamish invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Kyle Sherrill invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Fiorela Kapllanaj invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Bob Schulz is listed in a Chief Partnership Officer capacity at Nina Capital. No person-specific investment authority is inferred; the firm's mandate is retained only as shared context.

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Aline Noizet is listed in a Community Manager capacity at Nina Capital. No person-specific investment authority is inferred; the firm's mandate is retained only as shared context.

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Guillem Torruella invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..

Nina Capital

Check: Nina Capital does not publish one standard current check-size range on its official site.

Olivia Escudero invests or supports investment work through Nina Capital. Nina Capital's published strategy is to help thoughtful health-technology teams bridge from founding to Series A using a need-driven, value-based Biodesign approach..

APEX Ventures

Check: €500K-€2.5M, as published by APEX Ventures.

Andreas Riegler invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.

APEX Ventures

Check: €500K-€2.5M, as published by APEX Ventures.

Wolfgang Neubert invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.

APEX Ventures

Check: €500K-€2.5M, as published by APEX Ventures.

Stefan Haubner invests through APEX Ventures's published strategy: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.

APEX Ventures

Check: €500K-€2.5M, as published by APEX Ventures.

Marcell Farkas supports APEX Ventures, whose published strategy is: Back European deep-tech companies from Seed to Series A across AI, autonomous systems, robotics, energy transition, next-generation computing, medical technology and space.

Rock Health Capital

Check: Rock Health Capital does not publish a standard current check-size range on its official site.

Hylton Kalvaria is listed in a Advisor capacity at Rock Health Capital. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

Rock Health Capital

Check: Rock Health Capital does not publish a standard current check-size range on its official site.

Keith W. Anderson is listed in a Advisor capacity at Rock Health Capital. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

Rock Health Capital

Check: Rock Health Capital does not publish a standard current check-size range on its official site.

Monique Smith is listed in a Advisor capacity at Rock Health Capital. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

Rock Health Capital

Check: Rock Health Capital does not publish a standard current check-size range on its official site.

Bill Evans invests or supports investments through Rock Health Capital's published strategy: Invest in remarkable entrepreneurs working at the intersection of healthcare and technology to make healthcare massively better for every human being.

Rock Health Capital

Check: Rock Health Capital does not publish a standard current check-size range on its official site.

Sean Day invests or supports investments through Rock Health Capital's published strategy: Invest in remarkable entrepreneurs working at the intersection of healthcare and technology to make healthcare massively better for every human being.

Nina Capital

Barcelona, Spain

APEX Ventures

Vienna, Austria

Cottonwood Technology Fund

Denver, Colorado / Santa Fe, New Mexico / Amsterdam and Enschede, Netherlands

Ohio Innovation Fund

Dublin, Ohio

Rock Health Capital

San Francisco, California